GlassScriptPhysician profile
Susan Wonsiewicz Trout
NPI 1285635193
$1,251.36
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $217 · 2021: $350 · 2022: $269.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $553.83 | 2019-2022 | |
| Abbvie INC. | $144.73 | 2019-2022 | |
| Organon LLC | $107.65 | 2021-2022 | |
| Ibsa Pharma INC. | $97.50 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $84.58 | 2019-2020 | |
| Therapeuticsmd, INC. | $55.30 | 2019-2021 | |
| Teleflex LLC | $42.72 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $37.03 | 2019-2021 | |
| Emd Serono, INC. | $29.18 | 2021 | |
| Ferring Pharmaceuticals INC. | $28.44 | 2020 | |
| Alfasigma USA, INC. | $23.59 | 2021 | |
| Coopersurgical, INC. | $18.54 | 2019 | |
| Avion Pharmaceuticals | $17.06 | 2022 | |
| Covidien LP | $11.21 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Trout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.